person · Reporting owner

DENNER ALEXANDER J

Disclosed activity across 10 companies

Tapewire entity: 37234
SEC CIK: 0001361754

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
BIOGEN INC.BIIB · Entity 1675	Director	June 15, 2022	June 17, 2022
IRONWOOD PHARMACEUTICALS INCIRWD · Entity 5213	Director	September 15, 2026	September 17, 2026
Regulus Therapeutics Inc.RGLS · Entity 78034	10% owner	December 24, 2019	January 04, 2020
SEELOS THERAPEUTICS, INC.APRI · Entity 93662	10% owner	March 21, 2018	March 23, 2018
Sarissa Capital Acquisition Corp.SRSA · Entity 145567	10% owner	October 30, 2020	November 03, 2020

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

BIOGEN INC.

Report date June 15, 2022 · Filed June 17, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	15,099	Reported balance After 2022-06-15 transaction · row 1 1 source row Row 1 · 2022-06-15 · Grant · Acquired 1,370 · Balance 15,099
Common StockSEC Table I · non-derivative	IndirectSee Footnotes	643,000	Reported balance Holding disclosure · report date 2022-06-15 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 643,000 F1: Dr. Denner disclaims beneficial ownership of the shares being reported on this Form 4 except to the extent of his pecuniary interest therein. F2: Sarissa Capital Management LP ("Sarissa Capital") is the investment advisor to certain investment funds, including the funds that directly beneficially own the securities reported herein (the "Sarissa Funds"). Alexander Denner is the Chief Investment Officer of Sarissa Capital and controls the ultimate general partner of the Sarissa Funds. By virtue of the foregoing, Dr. Denner may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended) the shares that the Sarissa Funds directly beneficially own.

Filing footnotes · ownership attribution and instrument terms

F1: Dr. Denner disclaims beneficial ownership of the shares being reported on this Form 4 except to the extent of his pecuniary interest therein.

F2: Sarissa Capital Management LP ("Sarissa Capital") is the investment advisor to certain investment funds, including the funds that directly beneficially own the securities reported herein (the "Sarissa Funds"). Alexander Denner is the Chief Investment Officer of Sarissa Capital and controls the ultimate general partner of the Sarissa Funds. By virtue of the foregoing, Dr. Denner may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended) the shares that the Sarissa Funds directly beneficially own.

IRONWOOD PHARMACEUTICALS INC

Report date September 15, 2026 · Filed September 17, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	Direct	327,549	Reported balance After 2026-09-15 transaction · row 1 1 source row Row 1 · 2026-09-15 · Grant · Acquired 3,694 · Balance 327,549 F1: Issued pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024.

Filing footnotes · ownership attribution and instrument terms

F1: Issued pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024.

Regulus Therapeutics Inc.

Report date December 24, 2019 · Filed January 04, 2020

Jointly reported with Sarissa Capital Management LP, Sarissa Capital Offshore Master Fund LP, Sarissa Capital Catapult Fund LLC, Sarissa Capital Hawkeye Fund LP

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A-2 Convertible Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.67	IndirectSee Footnotes	423,162	Reported balance After 2019-12-24 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2019-12-24 · Purchase · Acquired 423,162 · Balance 423,162 F1: See Exhibit 99.1. F2: See Exhibit 99.1. F3: See Exhibit 99.1.
Warrants to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $6.66 · Expires 2024-12-24	IndirectSee Footnotes	6,083,471	Reported balance After 2019-12-24 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2019-12-24 · Purchase · Acquired 4,231,620 · Balance 6,083,471 F1: See Exhibit 99.1. F2: See Exhibit 99.1. F3: See Exhibit 99.1.

Filing footnotes · ownership attribution and instrument terms

F1: See Exhibit 99.1.

F2: See Exhibit 99.1.

F3: See Exhibit 99.1.

SEELOS THERAPEUTICS, INC.

Report date March 21, 2018 · Filed March 23, 2018

Jointly reported with Sarissa Capital Management LP, Sarissa Capital Offshore Master Fund LP

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Warrants to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.71 · Expires 2023-01-12	IndirectSee Footnote	0	Reported balance After 2018-03-21 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2018-03-21 · Other · Disposed 653,409 · Balance 0 F1: See Exhibit 99.1; Note 1. F2: See Exhibit 99.1; Note 2. F3: See Exhibit 99.1; Note 3.
Warrants to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.71 · Expires 2023-01-12	IndirectSee Footnote	653,409	Reported balance After 2018-03-21 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2018-03-21 · Other · Acquired 653,409 · Balance 653,409 F1: See Exhibit 99.1; Note 1. F2: See Exhibit 99.1; Note 2. F3: See Exhibit 99.1; Note 3.

Filing footnotes · ownership attribution and instrument terms

F1: See Exhibit 99.1; Note 1.

F2: See Exhibit 99.1; Note 2.

F3: See Exhibit 99.1; Note 3.

Sarissa Capital Acquisition Corp.

Report date October 30, 2020 · Filed November 03, 2020

Jointly reported with Sarissa Capital Acquisition Sponsor LLC, Sarissa Capital Management LP, Sarissa Capital Management GP LLC

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class B ordinary sharesSEC Table II · derivative / convertible security	Direct	5,000,000	Reported balance After 2020-10-30 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2020-10-30 · Other · Disposed 31,250 · Balance 5,000,000 F1: As described in the issuer's registration statement on Form S-1 (File No. 333-249171) under the heading "Description of Securities - Founder Shares," Class B ordinary shares of the issuer, par value $0.0001 per share ("Class B Shares"), will automatically convert into Class A ordinary shares of the issuer, par value $0.0001 per share ("Class A Shares"), at the time of the issuer's initial business combination, on a one-for-one basis, subject to certain adjustment, and have no expiration date. F2: Forfeiture to the issuer for no consideration because the underwriter for the issuer's initial public offering did not fully exercise the over-allotment option. F3: Sarissa Capital Management LP (the "Managing Member") is the managing member of Sarissa Capital Acquisition Sponsor LLC, the reporting person (the "Sponsor"), and as such, has voting and investment discretion with respect to the ordinary shares held of record by the Sponsor and may be deemed to have shared beneficial ownership of the ordinary shares held directly by the Sponsor. The general partner of the Managing Member is Sarissa Capital Management GP LLC, and the managing member of Sarissa Capital Management GP LLC is Alexander Denner. Alexander Denner also serves as the Chairman and Chief Executive Officer of the issuer. Both Sarissa Capital Management GP LLC and Alexander Denner may be deemed to have shared beneficial ownership of the ordinary shares held directly by the Sponsor. F4: (continued from footnote 3) Each of the issuer's officers and directors may hold a direct or indirect interest in the Sponsor. Each such person disclaims any beneficial ownership of the reported shares other than to the extent of any pecuniary interest they may have therein, directly or indirectly.

Filing footnotes · ownership attribution and instrument terms

F1: As described in the issuer's registration statement on Form S-1 (File No. 333-249171) under the heading "Description of Securities - Founder Shares," Class B ordinary shares of the issuer, par value $0.0001 per share ("Class B Shares"), will automatically convert into Class A ordinary shares of the issuer, par value $0.0001 per share ("Class A Shares"), at the time of the issuer's initial business combination, on a one-for-one basis, subject to certain adjustment, and have no expiration date.

F2: Forfeiture to the issuer for no consideration because the underwriter for the issuer's initial public offering did not fully exercise the over-allotment option.

F3: Sarissa Capital Management LP (the "Managing Member") is the managing member of Sarissa Capital Acquisition Sponsor LLC, the reporting person (the "Sponsor"), and as such, has voting and investment discretion with respect to the ordinary shares held of record by the Sponsor and may be deemed to have shared beneficial ownership of the ordinary shares held directly by the Sponsor. The general partner of the Managing Member is Sarissa Capital Management GP LLC, and the managing member of Sarissa Capital Management GP LLC is Alexander Denner. Alexander Denner also serves as the Chairman and Chief Executive Officer of the issuer. Both Sarissa Capital Management GP LLC and Alexander Denner may be deemed to have shared beneficial ownership of the ordinary shares held directly by the Sponsor.

F4: (continued from footnote 3) Each of the issuer's officers and directors may hold a direct or indirect interest in the Sponsor. Each such person disclaims any beneficial ownership of the reported shares other than to the extent of any pecuniary interest they may have therein, directly or indirectly.

Past disclosures · reporting ended (5)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ARIAD PHARMACEUTICALS INC

Report date February 16, 2017 · Filed February 16, 2017

Section 16 reporting ended · disclosed 2017-02-16. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2017-02-16 transaction · row 1 1 source row Row 1 · 2017-02-16 · Disposition to issuer · Disposed 53,173 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of January 8, 2017 (the "Merger Agreement"), between the Company, Takeda Pharmaceutical Company Limited ("Takeda") and Kiku Merger Co., Inc. ("Purchaser"), on February 16, 2017, Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive $24.00 in cash. F2: The number of Shares reported includes 5,508 unvested restricted Shares subject to a lapsing right of repurchase by the Company (each, a "Restricted Share") and 12,500 Shares underlying unvested restricted stock units (each, an "RSU"). By virtue of the Merger and without any required action on the part of the holder thereof, all vesting conditions and restrictions applicable to each Restricted Share lapsed and each Restricted Share was converted automatically into the right to receive $24.00 in cash. In addition, pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the Merger automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Merger into a vested right to receive a lump-sum cash payment in an amount equal to $24.00 for each Share underlying the RSU, less any required withholding taxes.
Common StockSEC Table I · non-derivative	IndirectSarissa Capital Domestic Fund LP	Reported balance After 2017-02-16 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2017-02-16 · Disposition to issuer · Disposed 7,798,665 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of January 8, 2017 (the "Merger Agreement"), between the Company, Takeda Pharmaceutical Company Limited ("Takeda") and Kiku Merger Co., Inc. ("Purchaser"), on February 16, 2017, Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive $24.00 in cash. F3: The reporting person is the Chief Investment Officer of Sarissa Capital Management LP, investment manager of this fund. As such, the reporting person may be deemed to beneficially own the securities owned by this fund. The reporting person disclaims any beneficial ownership of these securities, except to the extent of his pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSarissa Capital Offshore Master Fund LP	Reported balance After 2017-02-16 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2017-02-16 · Disposition to issuer · Disposed 5,051,335 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of January 8, 2017 (the "Merger Agreement"), between the Company, Takeda Pharmaceutical Company Limited ("Takeda") and Kiku Merger Co., Inc. ("Purchaser"), on February 16, 2017, Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive $24.00 in cash. F3: The reporting person is the Chief Investment Officer of Sarissa Capital Management LP, investment manager of this fund. As such, the reporting person may be deemed to beneficially own the securities owned by this fund. The reporting person disclaims any beneficial ownership of these securities, except to the extent of his pecuniary interest therein.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.73	Direct	Reported balance After 2017-02-16 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2017-02-16 · Disposition to issuer · Disposed 75,000 · Balance 0 F4: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.45	Direct	Reported balance After 2017-02-16 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2017-02-16 · Disposition to issuer · Disposed 25,000 · Balance 0 F4: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.91	Direct	Reported balance After 2017-02-16 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2017-02-16 · Disposition to issuer · Disposed 25,000 · Balance 0 F4: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.82	Direct	Reported balance After 2017-02-16 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2017-02-16 · Disposition to issuer · Disposed 25,000 · Balance 0 F4: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0.
3.625% Convertible Notes due 2019SEC Table II · derivative / convertible security · Conversion / exercise price $9.30	IndirectSarissa Capital Domestic Fund LP	Reported balance After 2017-02-16 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2017-02-16 · Disposition to issuer · Disposed 5,340,720 · Balance 0 F5: The reporting person is an indirect beneficial owner of the reported number of 3.635% Convertible Senior Notes due 2019 (the "Convertible Notes"). Following the consummation of the Merger, the Convertible Notes are solely convertible into $2,580.228 in cash (without interest) per $1,000 principal amount of Notes. However, if any of the Convertible Notes are converted on or after the date the Issuer gives notice of the occurrence of the Effective Date (as defined in the Indenture, dated as of June 17, 2014, between the Issuer and Wells Fargo Bank, National Association, a national banking association, as trustee (the "Indenture")) applicable to the Merger, and on or prior to 5:00 p.m. New York City time on the business day immediately prior to the Fundamental Change Repurchase Date (as defined in the Indenture) applicable to the Merger, the reporting person shall be entitled to receive, upon conversion, $2,592.0216 (without interest) per $1,000 principal amount of Convertible Notes. F3: The reporting person is the Chief Investment Officer of Sarissa Capital Management LP, investment manager of this fund. As such, the reporting person may be deemed to beneficially own the securities owned by this fund. The reporting person disclaims any beneficial ownership of these securities, except to the extent of his pecuniary interest therein.
3.625% Convertible Notes due 2019SEC Table II · derivative / convertible security · Conversion / exercise price $9.30	IndirectSarissa Capital Offshore Master Fund LP	Reported balance After 2017-02-16 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2017-02-16 · Disposition to issuer · Disposed 3,459,280 · Balance 0 F5: The reporting person is an indirect beneficial owner of the reported number of 3.635% Convertible Senior Notes due 2019 (the "Convertible Notes"). Following the consummation of the Merger, the Convertible Notes are solely convertible into $2,580.228 in cash (without interest) per $1,000 principal amount of Notes. However, if any of the Convertible Notes are converted on or after the date the Issuer gives notice of the occurrence of the Effective Date (as defined in the Indenture, dated as of June 17, 2014, between the Issuer and Wells Fargo Bank, National Association, a national banking association, as trustee (the "Indenture")) applicable to the Merger, and on or prior to 5:00 p.m. New York City time on the business day immediately prior to the Fundamental Change Repurchase Date (as defined in the Indenture) applicable to the Merger, the reporting person shall be entitled to receive, upon conversion, $2,592.0216 (without interest) per $1,000 principal amount of Convertible Notes. F3: The reporting person is the Chief Investment Officer of Sarissa Capital Management LP, investment manager of this fund. As such, the reporting person may be deemed to beneficially own the securities owned by this fund. The reporting person disclaims any beneficial ownership of these securities, except to the extent of his pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger, dated as of January 8, 2017 (the "Merger Agreement"), between the Company, Takeda Pharmaceutical Company Limited ("Takeda") and Kiku Merger Co., Inc. ("Purchaser"), on February 16, 2017, Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive $24.00 in cash.

F2: The number of Shares reported includes 5,508 unvested restricted Shares subject to a lapsing right of repurchase by the Company (each, a "Restricted Share") and 12,500 Shares underlying unvested restricted stock units (each, an "RSU"). By virtue of the Merger and without any required action on the part of the holder thereof, all vesting conditions and restrictions applicable to each Restricted Share lapsed and each Restricted Share was converted automatically into the right to receive $24.00 in cash. In addition, pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the Merger automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Merger into a vested right to receive a lump-sum cash payment in an amount equal to $24.00 for each Share underlying the RSU, less any required withholding taxes.

F3: The reporting person is the Chief Investment Officer of Sarissa Capital Management LP, investment manager of this fund. As such, the reporting person may be deemed to beneficially own the securities owned by this fund. The reporting person disclaims any beneficial ownership of these securities, except to the extent of his pecuniary interest therein.

F4: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0.

F5: The reporting person is an indirect beneficial owner of the reported number of 3.635% Convertible Senior Notes due 2019 (the "Convertible Notes"). Following the consummation of the Merger, the Convertible Notes are solely convertible into $2,580.228 in cash (without interest) per $1,000 principal amount of Notes. However, if any of the Convertible Notes are converted on or after the date the Issuer gives notice of the occurrence of the Effective Date (as defined in the Indenture, dated as of June 17, 2014, between the Issuer and Wells Fargo Bank, National Association, a national banking association, as trustee (the "Indenture")) applicable to the Merger, and on or prior to 5:00 p.m. New York City time on the business day immediately prior to the Fundamental Change Repurchase Date (as defined in the Indenture) applicable to the Merger, the reporting person shall be entitled to receive, upon conversion, $2,592.0216 (without interest) per $1,000 principal amount of Convertible Notes.

Bioverativ Inc.

Report date March 08, 2018 · Filed March 08, 2018

Section 16 reporting ended · disclosed 2018-03-08. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2018-03-08 transaction · row 1 1 source row Row 1 · 2018-03-08 · Disposition to issuer · Disposed 5,001 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of January 21, 2018 (the "Merger Agreement"), between the Company, Sanofi, a French soci?t? anonyme (the "Parent"), and Blink Acquisition Corp. ("Merger Sub"), on March 8, 2018, Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive $105.00 in cash.
Common StockSEC Table I · non-derivative	IndirectSee footnote	Reported balance After 2018-03-08 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2018-03-08 · Disposition to issuer · Disposed 1,165,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of January 21, 2018 (the "Merger Agreement"), between the Company, Sanofi, a French soci?t? anonyme (the "Parent"), and Blink Acquisition Corp. ("Merger Sub"), on March 8, 2018, Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive $105.00 in cash. F2: All Shares reported herein are beneficially owned by Sarissa Capital Master Offshore Fund LP, a Cayman Island exempted limited partnership ("Sarissa Offshore"). Sarissa Capital Management GP LLC, a Delaware limited liability company ("Sarissa Capital GP"), is the general partner of Sarissa Capital Management LP, a Delaware limited partnership ("Sarissa Capital"), the investment advisor to Sarissa Offshore. Alexander Denner, Ph.D. is the Chief Investment Officer of Sarissa Capital and the managing member of Sarissa Capital GP. By virtue of the foregoing, Dr. Denner may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended) the Shares that Sarissa Offshore directly beneficially owns. Dr. Denner disclaims beneficial ownership of these Shares except to the extent of his pecuniary interest therein.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2018-03-08 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2018-03-08 · Disposition to issuer · Disposed 5,455 · Balance 0 F3: Each restricted stock unit ("RSU") represents a contingent right to receive one Share of the issuer's common stock. F4: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the "Offer") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes.
Non-Qualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $44.51	Direct	Reported balance After 2018-03-08 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2018-03-08 · Disposition to issuer · Disposed 26,818 · Balance 0 F5: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger, dated as of January 21, 2018 (the "Merger Agreement"), between the Company, Sanofi, a French soci?t? anonyme (the "Parent"), and Blink Acquisition Corp. ("Merger Sub"), on March 8, 2018, Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive $105.00 in cash.

F2: All Shares reported herein are beneficially owned by Sarissa Capital Master Offshore Fund LP, a Cayman Island exempted limited partnership ("Sarissa Offshore"). Sarissa Capital Management GP LLC, a Delaware limited liability company ("Sarissa Capital GP"), is the general partner of Sarissa Capital Management LP, a Delaware limited partnership ("Sarissa Capital"), the investment advisor to Sarissa Offshore. Alexander Denner, Ph.D. is the Chief Investment Officer of Sarissa Capital and the managing member of Sarissa Capital GP. By virtue of the foregoing, Dr. Denner may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended) the Shares that Sarissa Offshore directly beneficially owns. Dr. Denner disclaims beneficial ownership of these Shares except to the extent of his pecuniary interest therein.

F3: Each restricted stock unit ("RSU") represents a contingent right to receive one Share of the issuer's common stock.

F4: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the "Offer") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes.

F5: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option.

Innoviva, Inc.

Report date March 04, 2025 · Filed March 18, 2025 · Amendment

Jointly reported with Sarissa Capital Management LP

Section 16 reporting ended · disclosed 2025-03-18. Current position is not established by this disclosure.

Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.

No balance rows disclosed in this filing.

Iterum Therapeutics plc

Report date February 11, 2021 · Filed February 12, 2021

Jointly reported with Sarissa Capital Management LP, Sarissa Capital Offshore Master Fund LP, Sarissa Capital Catapult Fund LLC, Sarissa Capital Hawkeye Fund LP, Sarissa Capital Master Fund II LP

Section 16 reporting ended · disclosed 2021-02-12. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	IndirectSee footnotes	20,616,949	Reported balance After 2021-02-11 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2021-02-11 · Conversion · Acquired 20,619,949 · Balance 20,616,949 F1: Dr. Denner, Sarissa Capital and the Sarissa Funds (each as defined below and, collectively, the "Reporting Persons") beneficially owned $15,00,000 principal amount of the Issuer's 6.500% Exchangeable Senior Subordinated Notes due 2025 (the "Exchangeable Notes"), which became exchangeable into the Issuer's Ordinary Shares at the option of the holder on January 21, 2021. On February 11, 2021, all of the Exchangeable Notes held by the Reporting Persons (inclusive of accrued interest) were exchanged for 20,619,949 Ordinary Shares. F2: (continued from footnote 1) As a result of the exchange (i) Sarissa Capital Offshore Master Fund LP, a Cayman Islands exempted limited partnership ("Sarissa Offshore"), was the direct beneficial owner of 12,126,791, (ii) Sarissa Capital Catapult Fund LLC, a Delaware limited liability company ("Sarissa Catapult") was the direct beneficial owner of 4,727,467 Ordinary Shares, (iii) Sarissa Capital Hawkeye Fund LP, a Delaware limited partnership ("Sarissa Hawkeye") was the direct beneficial owner of 3,520,513 Ordinary Shares and (iv) Sarissa Capital Master Fund II, a Delaware limited partnership ("Sarissa Master II" and, together with Sarissa Offshore, Sarissa Catapult, and Sarissa Hawkeye, the "Sarissa Funds") was the direct beneficial owner of 245,178 Ordinary Shares. F3: Following the exchange, on February 11, 2021, the Reporting Persons sold, in the aggregate, 10,000,000 Ordinary Shares at a volume weighted average price of $2.59 per share. These shares were sold in multiple open market transactions at prices ranging from $2.58 to $2.70. Of the aggregate amount of Ordinary Shares sold on February 11, 2021 by the Reporting Persons (i) Sarissa Offshore sold 5,881,300 Ordinary Shares, (ii) Sarissa Catapult sold 2,292,700 Ordinary Shares, (iii) Sarissa Hawkeye sold 1,707,300 Ordinary Shares and (iv) Sarissa Master II sold 118,700 Ordinary Shares. F6: Sarissa Capital Management LP, a Delaware limited partnership ("Sarissa Capital"), is the investment advisor to the Sarissa Funds and may be deemed to have beneficial ownership over the Ordinary Shares directly beneficially owned by the Sarissa Funds by virtue of the authority granted to it to vote and to dispose of the securities held by them, including the Ordinary Shares. Alexander J. Denner, Ph.D., a citizen of the United States of America ("Dr. Denner"), is the Chief Investment Officer of Sarissa Capital and the ultimate general partner of Sarissa Capital, Sarissa Offshore, Sarissa Hawkeye, Sarissa Master II, and the managing member of Sarissa Catapult is controlled by Dr. Denner; accordingly, Dr. Denner may be deemed to have beneficial ownership over the Ordinary Shares directly beneficially owned by the Sarissa Funds by virtue of such positions. F7: Each of Dr. Denner, Sarissa Capital, Sarissa Offshore, Sarissa Catapult, Sarissa Hawkeye and Sarissa Master II disclaims beneficial ownership of the Ordinary Shares except, in each case, to the extent of their pecuniary interest therein.
Ordinary SharesSEC Table I · non-derivative	IndirectSee footnotes	10,619,949	Reported balance After 2021-02-11 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2021-02-11 · Sale · Disposed 10,000,000 · Balance 10,619,949 F1: Dr. Denner, Sarissa Capital and the Sarissa Funds (each as defined below and, collectively, the "Reporting Persons") beneficially owned $15,00,000 principal amount of the Issuer's 6.500% Exchangeable Senior Subordinated Notes due 2025 (the "Exchangeable Notes"), which became exchangeable into the Issuer's Ordinary Shares at the option of the holder on January 21, 2021. On February 11, 2021, all of the Exchangeable Notes held by the Reporting Persons (inclusive of accrued interest) were exchanged for 20,619,949 Ordinary Shares. F2: (continued from footnote 1) As a result of the exchange (i) Sarissa Capital Offshore Master Fund LP, a Cayman Islands exempted limited partnership ("Sarissa Offshore"), was the direct beneficial owner of 12,126,791, (ii) Sarissa Capital Catapult Fund LLC, a Delaware limited liability company ("Sarissa Catapult") was the direct beneficial owner of 4,727,467 Ordinary Shares, (iii) Sarissa Capital Hawkeye Fund LP, a Delaware limited partnership ("Sarissa Hawkeye") was the direct beneficial owner of 3,520,513 Ordinary Shares and (iv) Sarissa Capital Master Fund II, a Delaware limited partnership ("Sarissa Master II" and, together with Sarissa Offshore, Sarissa Catapult, and Sarissa Hawkeye, the "Sarissa Funds") was the direct beneficial owner of 245,178 Ordinary Shares. F3: Following the exchange, on February 11, 2021, the Reporting Persons sold, in the aggregate, 10,000,000 Ordinary Shares at a volume weighted average price of $2.59 per share. These shares were sold in multiple open market transactions at prices ranging from $2.58 to $2.70. Of the aggregate amount of Ordinary Shares sold on February 11, 2021 by the Reporting Persons (i) Sarissa Offshore sold 5,881,300 Ordinary Shares, (ii) Sarissa Catapult sold 2,292,700 Ordinary Shares, (iii) Sarissa Hawkeye sold 1,707,300 Ordinary Shares and (iv) Sarissa Master II sold 118,700 Ordinary Shares. F5: The Reporting Persons undertake to provide any securityholder of the Issuer, the Issuer or the SEC Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote to this Form 4. F6: Sarissa Capital Management LP, a Delaware limited partnership ("Sarissa Capital"), is the investment advisor to the Sarissa Funds and may be deemed to have beneficial ownership over the Ordinary Shares directly beneficially owned by the Sarissa Funds by virtue of the authority granted to it to vote and to dispose of the securities held by them, including the Ordinary Shares. Alexander J. Denner, Ph.D., a citizen of the United States of America ("Dr. Denner"), is the Chief Investment Officer of Sarissa Capital and the ultimate general partner of Sarissa Capital, Sarissa Offshore, Sarissa Hawkeye, Sarissa Master II, and the managing member of Sarissa Catapult is controlled by Dr. Denner; accordingly, Dr. Denner may be deemed to have beneficial ownership over the Ordinary Shares directly beneficially owned by the Sarissa Funds by virtue of such positions. F7: Each of Dr. Denner, Sarissa Capital, Sarissa Offshore, Sarissa Catapult, Sarissa Hawkeye and Sarissa Master II disclaims beneficial ownership of the Ordinary Shares except, in each case, to the extent of their pecuniary interest therein.
Ordinary SharesSEC Table I · non-derivative	IndirectSee footnotes	0	Reported balance After 2021-02-12 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2021-02-12 · Sale · Disposed 10,619,949 · Balance 0 F1: Dr. Denner, Sarissa Capital and the Sarissa Funds (each as defined below and, collectively, the "Reporting Persons") beneficially owned $15,00,000 principal amount of the Issuer's 6.500% Exchangeable Senior Subordinated Notes due 2025 (the "Exchangeable Notes"), which became exchangeable into the Issuer's Ordinary Shares at the option of the holder on January 21, 2021. On February 11, 2021, all of the Exchangeable Notes held by the Reporting Persons (inclusive of accrued interest) were exchanged for 20,619,949 Ordinary Shares. F2: (continued from footnote 1) As a result of the exchange (i) Sarissa Capital Offshore Master Fund LP, a Cayman Islands exempted limited partnership ("Sarissa Offshore"), was the direct beneficial owner of 12,126,791, (ii) Sarissa Capital Catapult Fund LLC, a Delaware limited liability company ("Sarissa Catapult") was the direct beneficial owner of 4,727,467 Ordinary Shares, (iii) Sarissa Capital Hawkeye Fund LP, a Delaware limited partnership ("Sarissa Hawkeye") was the direct beneficial owner of 3,520,513 Ordinary Shares and (iv) Sarissa Capital Master Fund II, a Delaware limited partnership ("Sarissa Master II" and, together with Sarissa Offshore, Sarissa Catapult, and Sarissa Hawkeye, the "Sarissa Funds") was the direct beneficial owner of 245,178 Ordinary Shares. F4: On February 12, 2021, the Reporting Persons sold, in the aggregate 10,619,949 Ordinary Shares at a volume weighted average price of $2.27 per share. These shares were sold in multiple open market transactions at prices ranging from $2.24 to $2.27. Of the aggregate amount of Ordinary Shares sold on February 12, 2021 by the Reporting Persons (i) Sarissa Offshore sold 6,245,491 Ordinary Shares, (ii) Sarissa Catapult sold 2,434,767 Ordinary Shares, (iii) Sarissa Hawkeye sold 1,813,213 Ordinary Shares and (iv) Sarissa Master II sold 126,478 Ordinary Shares. F5: The Reporting Persons undertake to provide any securityholder of the Issuer, the Issuer or the SEC Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote to this Form 4. F6: Sarissa Capital Management LP, a Delaware limited partnership ("Sarissa Capital"), is the investment advisor to the Sarissa Funds and may be deemed to have beneficial ownership over the Ordinary Shares directly beneficially owned by the Sarissa Funds by virtue of the authority granted to it to vote and to dispose of the securities held by them, including the Ordinary Shares. Alexander J. Denner, Ph.D., a citizen of the United States of America ("Dr. Denner"), is the Chief Investment Officer of Sarissa Capital and the ultimate general partner of Sarissa Capital, Sarissa Offshore, Sarissa Hawkeye, Sarissa Master II, and the managing member of Sarissa Catapult is controlled by Dr. Denner; accordingly, Dr. Denner may be deemed to have beneficial ownership over the Ordinary Shares directly beneficially owned by the Sarissa Funds by virtue of such positions. F7: Each of Dr. Denner, Sarissa Capital, Sarissa Offshore, Sarissa Catapult, Sarissa Hawkeye and Sarissa Master II disclaims beneficial ownership of the Ordinary Shares except, in each case, to the extent of their pecuniary interest therein.
6.500% Exchangeable Senior Subordinated Note due 2025SEC Table II · derivative / convertible security · Expires 2025-01-31	IndirectSee Footnotes	0	Reported balance After 2021-02-11 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2021-02-11 · Conversion · Disposed 15,000,000 · Balance 0 F1: Dr. Denner, Sarissa Capital and the Sarissa Funds (each as defined below and, collectively, the "Reporting Persons") beneficially owned $15,00,000 principal amount of the Issuer's 6.500% Exchangeable Senior Subordinated Notes due 2025 (the "Exchangeable Notes"), which became exchangeable into the Issuer's Ordinary Shares at the option of the holder on January 21, 2021. On February 11, 2021, all of the Exchangeable Notes held by the Reporting Persons (inclusive of accrued interest) were exchanged for 20,619,949 Ordinary Shares. F2: (continued from footnote 1) As a result of the exchange (i) Sarissa Capital Offshore Master Fund LP, a Cayman Islands exempted limited partnership ("Sarissa Offshore"), was the direct beneficial owner of 12,126,791, (ii) Sarissa Capital Catapult Fund LLC, a Delaware limited liability company ("Sarissa Catapult") was the direct beneficial owner of 4,727,467 Ordinary Shares, (iii) Sarissa Capital Hawkeye Fund LP, a Delaware limited partnership ("Sarissa Hawkeye") was the direct beneficial owner of 3,520,513 Ordinary Shares and (iv) Sarissa Capital Master Fund II, a Delaware limited partnership ("Sarissa Master II" and, together with Sarissa Offshore, Sarissa Catapult, and Sarissa Hawkeye, the "Sarissa Funds") was the direct beneficial owner of 245,178 Ordinary Shares. F5: The Reporting Persons undertake to provide any securityholder of the Issuer, the Issuer or the SEC Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote to this Form 4. F6: Sarissa Capital Management LP, a Delaware limited partnership ("Sarissa Capital"), is the investment advisor to the Sarissa Funds and may be deemed to have beneficial ownership over the Ordinary Shares directly beneficially owned by the Sarissa Funds by virtue of the authority granted to it to vote and to dispose of the securities held by them, including the Ordinary Shares. Alexander J. Denner, Ph.D., a citizen of the United States of America ("Dr. Denner"), is the Chief Investment Officer of Sarissa Capital and the ultimate general partner of Sarissa Capital, Sarissa Offshore, Sarissa Hawkeye, Sarissa Master II, and the managing member of Sarissa Catapult is controlled by Dr. Denner; accordingly, Dr. Denner may be deemed to have beneficial ownership over the Ordinary Shares directly beneficially owned by the Sarissa Funds by virtue of such positions. F7: Each of Dr. Denner, Sarissa Capital, Sarissa Offshore, Sarissa Catapult, Sarissa Hawkeye and Sarissa Master II disclaims beneficial ownership of the Ordinary Shares except, in each case, to the extent of their pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Dr. Denner, Sarissa Capital and the Sarissa Funds (each as defined below and, collectively, the "Reporting Persons") beneficially owned $15,00,000 principal amount of the Issuer's 6.500% Exchangeable Senior Subordinated Notes due 2025 (the "Exchangeable Notes"), which became exchangeable into the Issuer's Ordinary Shares at the option of the holder on January 21, 2021. On February 11, 2021, all of the Exchangeable Notes held by the Reporting Persons (inclusive of accrued interest) were exchanged for 20,619,949 Ordinary Shares.

F2: (continued from footnote 1) As a result of the exchange (i) Sarissa Capital Offshore Master Fund LP, a Cayman Islands exempted limited partnership ("Sarissa Offshore"), was the direct beneficial owner of 12,126,791, (ii) Sarissa Capital Catapult Fund LLC, a Delaware limited liability company ("Sarissa Catapult") was the direct beneficial owner of 4,727,467 Ordinary Shares, (iii) Sarissa Capital Hawkeye Fund LP, a Delaware limited partnership ("Sarissa Hawkeye") was the direct beneficial owner of 3,520,513 Ordinary Shares and (iv) Sarissa Capital Master Fund II, a Delaware limited partnership ("Sarissa Master II" and, together with Sarissa Offshore, Sarissa Catapult, and Sarissa Hawkeye, the "Sarissa Funds") was the direct beneficial owner of 245,178 Ordinary Shares.

F3: Following the exchange, on February 11, 2021, the Reporting Persons sold, in the aggregate, 10,000,000 Ordinary Shares at a volume weighted average price of $2.59 per share. These shares were sold in multiple open market transactions at prices ranging from $2.58 to $2.70. Of the aggregate amount of Ordinary Shares sold on February 11, 2021 by the Reporting Persons (i) Sarissa Offshore sold 5,881,300 Ordinary Shares, (ii) Sarissa Catapult sold 2,292,700 Ordinary Shares, (iii) Sarissa Hawkeye sold 1,707,300 Ordinary Shares and (iv) Sarissa Master II sold 118,700 Ordinary Shares.

F4: On February 12, 2021, the Reporting Persons sold, in the aggregate 10,619,949 Ordinary Shares at a volume weighted average price of $2.27 per share. These shares were sold in multiple open market transactions at prices ranging from $2.24 to $2.27. Of the aggregate amount of Ordinary Shares sold on February 12, 2021 by the Reporting Persons (i) Sarissa Offshore sold 6,245,491 Ordinary Shares, (ii) Sarissa Catapult sold 2,434,767 Ordinary Shares, (iii) Sarissa Hawkeye sold 1,813,213 Ordinary Shares and (iv) Sarissa Master II sold 126,478 Ordinary Shares.

F5: The Reporting Persons undertake to provide any securityholder of the Issuer, the Issuer or the SEC Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote to this Form 4.

F6: Sarissa Capital Management LP, a Delaware limited partnership ("Sarissa Capital"), is the investment advisor to the Sarissa Funds and may be deemed to have beneficial ownership over the Ordinary Shares directly beneficially owned by the Sarissa Funds by virtue of the authority granted to it to vote and to dispose of the securities held by them, including the Ordinary Shares. Alexander J. Denner, Ph.D., a citizen of the United States of America ("Dr. Denner"), is the Chief Investment Officer of Sarissa Capital and the ultimate general partner of Sarissa Capital, Sarissa Offshore, Sarissa Hawkeye, Sarissa Master II, and the managing member of Sarissa Catapult is controlled by Dr. Denner; accordingly, Dr. Denner may be deemed to have beneficial ownership over the Ordinary Shares directly beneficially owned by the Sarissa Funds by virtue of such positions.

F7: Each of Dr. Denner, Sarissa Capital, Sarissa Offshore, Sarissa Catapult, Sarissa Hawkeye and Sarissa Master II disclaims beneficial ownership of the Ordinary Shares except, in each case, to the extent of their pecuniary interest therein.

MEDICINES CO /DE

Report date January 06, 2020 · Filed January 06, 2020

Section 16 reporting ended · disclosed 2020-01-06. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2020-01-06 transaction · row 1 1 source row Row 1 · 2020-01-06 · Disposition to issuer · Disposed 85,813 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of November 23, 2019 (the "Merger Agreement"), by and among the Company, Novartis AG ("Parent") and Medusa Merger Corporation ("Purchaser"), on January 6, 2020, Purchaser was merged with and into the Company (the "Merger"), with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent. Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each a "Share") was converted into the right to receive $85.00 per Share, net to the seller in cash (the "Offer Price"). F2: The number of Shares reported includes 3,663 unvested restricted Shares (each a "Restricted Share"). Each Restricted Share that was outstanding immediately prior to the consummation of the tender offer by Parent and Purchaser automatically became fully vested as of immediately prior to, and contingent upon, the effective time of the Merger and was treated in the same manner as an outstanding Share.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	Reported balance After 2020-01-06 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2020-01-06 · Disposition to issuer · Disposed 4,202,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of November 23, 2019 (the "Merger Agreement"), by and among the Company, Novartis AG ("Parent") and Medusa Merger Corporation ("Purchaser"), on January 6, 2020, Purchaser was merged with and into the Company (the "Merger"), with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent. Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each a "Share") was converted into the right to receive $85.00 per Share, net to the seller in cash (the "Offer Price"). F3: The shares reported herein as being indirectly beneficially owned by Dr. Denner are directly beneficially owned by funds managed and/or controlled by Sarissa Capital Management LP. Dr. Denner is the Chief Investment Officer of Sarissa Capital Management LP and controls the general partner of Sarissa Capital Management LP. By virtue of the foregoing, Dr. Denner may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended) these shares. Dr. Denner disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $32.86	Direct	Reported balance After 2020-01-06 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-01-06 · Disposition to issuer · Disposed 27,230 · Balance 0 F4: Pursuant to the Merger Agreement, each option (each an "Option") that was outstanding immediately prior to the consummation of the tender offer by Parent and Purchaser, whether vested or unvested, became fully vested and was canceled as of immediately prior to, and contingent upon, the effective time of the Merger, in exchange for the right to receive an amount in cash equal to the product of (x) the excess (if any) of the Offer Price over the per share exercise price payable in respect of each Share issuable under such Option, multiplied by (y) the number of Shares issuable under such Option.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $37.22	Direct	Reported balance After 2020-01-06 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-01-06 · Disposition to issuer · Disposed 9,700 · Balance 0 F4: Pursuant to the Merger Agreement, each option (each an "Option") that was outstanding immediately prior to the consummation of the tender offer by Parent and Purchaser, whether vested or unvested, became fully vested and was canceled as of immediately prior to, and contingent upon, the effective time of the Merger, in exchange for the right to receive an amount in cash equal to the product of (x) the excess (if any) of the Offer Price over the per share exercise price payable in respect of each Share issuable under such Option, multiplied by (y) the number of Shares issuable under such Option.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $39.39	Direct	Reported balance After 2020-01-06 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2020-01-06 · Disposition to issuer · Disposed 8,577 · Balance 0 F4: Pursuant to the Merger Agreement, each option (each an "Option") that was outstanding immediately prior to the consummation of the tender offer by Parent and Purchaser, whether vested or unvested, became fully vested and was canceled as of immediately prior to, and contingent upon, the effective time of the Merger, in exchange for the right to receive an amount in cash equal to the product of (x) the excess (if any) of the Offer Price over the per share exercise price payable in respect of each Share issuable under such Option, multiplied by (y) the number of Shares issuable under such Option.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $33.86	Direct	Reported balance After 2020-01-06 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2020-01-06 · Disposition to issuer · Disposed 9,141 · Balance 0 F4: Pursuant to the Merger Agreement, each option (each an "Option") that was outstanding immediately prior to the consummation of the tender offer by Parent and Purchaser, whether vested or unvested, became fully vested and was canceled as of immediately prior to, and contingent upon, the effective time of the Merger, in exchange for the right to receive an amount in cash equal to the product of (x) the excess (if any) of the Offer Price over the per share exercise price payable in respect of each Share issuable under such Option, multiplied by (y) the number of Shares issuable under such Option.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $34.81	Direct	Reported balance After 2020-01-06 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2020-01-06 · Disposition to issuer · Disposed 13,410 · Balance 0 F4: Pursuant to the Merger Agreement, each option (each an "Option") that was outstanding immediately prior to the consummation of the tender offer by Parent and Purchaser, whether vested or unvested, became fully vested and was canceled as of immediately prior to, and contingent upon, the effective time of the Merger, in exchange for the right to receive an amount in cash equal to the product of (x) the excess (if any) of the Offer Price over the per share exercise price payable in respect of each Share issuable under such Option, multiplied by (y) the number of Shares issuable under such Option.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger, dated as of November 23, 2019 (the "Merger Agreement"), by and among the Company, Novartis AG ("Parent") and Medusa Merger Corporation ("Purchaser"), on January 6, 2020, Purchaser was merged with and into the Company (the "Merger"), with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent. Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each a "Share") was converted into the right to receive $85.00 per Share, net to the seller in cash (the "Offer Price").

F2: The number of Shares reported includes 3,663 unvested restricted Shares (each a "Restricted Share"). Each Restricted Share that was outstanding immediately prior to the consummation of the tender offer by Parent and Purchaser automatically became fully vested as of immediately prior to, and contingent upon, the effective time of the Merger and was treated in the same manner as an outstanding Share.

F3: The shares reported herein as being indirectly beneficially owned by Dr. Denner are directly beneficially owned by funds managed and/or controlled by Sarissa Capital Management LP. Dr. Denner is the Chief Investment Officer of Sarissa Capital Management LP and controls the general partner of Sarissa Capital Management LP. By virtue of the foregoing, Dr. Denner may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended) these shares. Dr. Denner disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

F4: Pursuant to the Merger Agreement, each option (each an "Option") that was outstanding immediately prior to the consummation of the tender offer by Parent and Purchaser, whether vested or unvested, became fully vested and was canceled as of immediately prior to, and contingent upon, the effective time of the Merger, in exchange for the right to receive an amount in cash equal to the product of (x) the excess (if any) of the Offer Price over the per share exercise price payable in respect of each Share issuable under such Option, multiplied by (y) the number of Shares issuable under such Option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
September 15, 2026 Filed Sep 17, 2026 20:05 UTC	IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213	GrantClass A Common Stock	3,694	$0.00	$0.00	Disclosure SEC source: 0001193125-26-394323 · ownership.xml · nonDerivative · entry 1 DENNER ALEXANDER J · CIK 0001361754 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 327,549 F1 · kind: Issued pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024. Read SEC document
June 16, 2026 Filed Jun 17, 2026 20:42 UTC	IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213	GrantClass A Common Stock	63,481	$0.00	$0.00	Disclosure SEC source: 0001193125-26-274279 · ownership.xml · nonDerivative · entry 2 DENNER ALEXANDER J · CIK 0001361754 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 323,855 F2 · kind: The restricted stock, granted pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year. Read SEC document
June 15, 2026 Filed Jun 17, 2026 20:42 UTC	IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213	GrantClass A Common Stock	4,065	$0.00	$0.00	Disclosure SEC source: 0001193125-26-274279 · ownership.xml · nonDerivative · entry 1 DENNER ALEXANDER J · CIK 0001361754 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 260,374 F1 · kind: Issued pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024. Read SEC document
March 17, 2026 Filed Mar 18, 2026 00:34 UTC	IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213	SaleClass A Common Stock	5,800	$3.31	$19,198.00	Disclosure SEC source: 0001193125-26-111581 · ownership.xml · nonDerivative · entry 3 DENNER ALEXANDER J · CIK 0001361754 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 9,188,635 F2 · ownership.nature: Consists of shares that are held by Sarissa Capital Management LP ("Sarissa Capital") or by the funds and other investment vehicles (the "Sarissa Funds") for which Sarissa Capital serves as investment advisor. Dr. Denner is the Chief Investment Officer of Sarissa Capital and the managing member, general partner or other control party of the Sarissa Funds. By virtue of the foregoing, Dr. Denner may be deemed to indirectly beneficially own the shares that these funds directly beneficially own. Each of SarissaCapital, the Sarissa Funds and Dr. Denner disclaims beneficial ownership of these shares except, in each case, to the extent of their pecuniary interest therein. Read SEC document
March 17, 2026 Filed Mar 18, 2026 00:34 UTC	IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213	SaleClass A Common Stock	6,725,000	$3.05	$20,511,250.00	Disclosure SEC source: 0001193125-26-111581 · ownership.xml · nonDerivative · entry 2 DENNER ALEXANDER J · CIK 0001361754 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 9,194,435 F2 · ownership.nature: Consists of shares that are held by Sarissa Capital Management LP ("Sarissa Capital") or by the funds and other investment vehicles (the "Sarissa Funds") for which Sarissa Capital serves as investment advisor. Dr. Denner is the Chief Investment Officer of Sarissa Capital and the managing member, general partner or other control party of the Sarissa Funds. By virtue of the foregoing, Dr. Denner may be deemed to indirectly beneficially own the shares that these funds directly beneficially own. Each of SarissaCapital, the Sarissa Funds and Dr. Denner disclaims beneficial ownership of these shares except, in each case, to the extent of their pecuniary interest therein. Read SEC document
March 13, 2026 Filed Mar 18, 2026 00:34 UTC	IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213	GrantClass A Common Stock	4,451	$0.00	$0.00	Disclosure SEC source: 0001193125-26-111581 · ownership.xml · nonDerivative · entry 1 DENNER ALEXANDER J · CIK 0001361754 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 256,309 F1 · kind: Issued pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024. Read SEC document
December 15, 2025 Filed Dec 17, 2025 21:05 UTC	IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213	GrantClass A Common Stock	4,178	$0.00	$0.00	Disclosure SEC source: 0001193125-25-322690 · ownership.xml · nonDerivative · entry 1 DENNER ALEXANDER J · CIK 0001361754 · Director · 10% owner Sarissa Capital Management LP · CIK 0001577524 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 251,858 F1 · kind: Issued pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024. Read SEC document
September 15, 2025 Filed Sep 18, 2025 00:28 UTC	IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213	GrantClass A Common Stock	11,718	$0.00	$0.00	Disclosure SEC source: 0001193125-25-206547 · ownership.xml · nonDerivative · entry 1 DENNER ALEXANDER J · CIK 0001361754 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 247,680 F1 · kind: Issued pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024. Read SEC document
June 13, 2025 Filed Jun 17, 2025 20:05 UTC	IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213	GrantClass A Common Stock	24,193	$0.00	$0.00	Disclosure SEC source: 0000950170-25-087350 · ownership.xml · nonDerivative · entry 1 DENNER ALEXANDER J · CIK 0001361754 · Director · 10% owner Sarissa Capital Management LP · CIK 0001577524 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 235,962 F1 · kind: Issued pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024. Read SEC document
June 10, 2025 Filed Jun 12, 2025 20:17 UTC	IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213	GrantClass A Common Stock	45,000	$0.00	$0.00	Disclosure SEC source: 0000950170-25-085378 · ownership.xml · nonDerivative · entry 1 DENNER ALEXANDER J · CIK 0001361754 · Director · 10% owner Sarissa Capital Management LP · CIK 0001577524 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 211,769 F1 · kind: The restricted stock, granted pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year. Read SEC document
April 02, 2025 Filed Apr 4, 2025 20:05 UTC	IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213	GrantClass A Common Stock	10,416	$0.00	$0.00	Disclosure SEC source: 0000950170-25-051106 · ownership.xml · nonDerivative · entry 1 DENNER ALEXANDER J · CIK 0001361754 · Director · 10% owner Sarissa Capital Management LP · CIK 0001577524 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 166,769 F1 · kind: Issued pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024. Read SEC document
March 06, 2025 Filed Mar 7, 2025 02:30 UTC	Innoviva, Inc. INVA · Entity 4679	SaleCommon Stock, par value $0.01 per share	1,196,746	$17.52	$20,964,237.40	Disclosure SEC source: 0000899140-25-000405 · form4.xml · nonDerivative · entry 3 DENNER ALEXANDER J · CIK 0001361754 · 10% owner Sarissa Capital Management LP · CIK 0001577524 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 5,658,705 F3 · price: On March 6, 2025, the Reporting Persons sold 1,196,746 shares of Common Stock at a weighted average price of $17.5177 per share. The shares were sold in multiple open market transactions at prices ranging from $17.48 to $17.64 per share, inclusive. The Reporting Persons undertake to provide, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. F4 · ownership.nature: Sarissa Capital Management LP ("Sarissa Capital") is the investment advisor to Sarissa Capital Offshore Master Fund LP, Sarissa Capital Catapult Fund LLC, Sarissa Capital Hawkeye Fund LP and Sarissa Capital Master Fund II LP (collectively, the "Sarissa Funds") and may be deemed to beneficially own the shares of Common Stock directly beneficially owned by the Sarissa Funds by virtue of the authority granted to it to vote and to dispose of the securities held by them, including the shares of Common Stock. Alexander J. Denner, Ph.D., a citizen of the United States of America ("Dr. Denner"), is the Chief Investment Officer and ultimate general partner of Sarissa Capital and is the ultimate general partner, or controls the managing member, of each of the Sarissa Funds; accordingly, Dr. Denner may be deemed to beneficially own the shares of Common Stock directly held by the Sarissa Funds by virtue of such positions. F5 · ownership.nature: Each of Dr. Denner, Sarissa Capital and each of the Sarissa Funds disclaims beneficial ownership of the shares of Common Stock reported herein except, in each case, to the extent of their pecuniary interest therein. Read SEC document
March 05, 2025 Filed Mar 7, 2025 02:30 UTC	Innoviva, Inc. INVA · Entity 4679	SaleCommon Stock, par value $0.01 per share	270,374	$17.63	$4,766,125.83	Disclosure SEC source: 0000899140-25-000405 · form4.xml · nonDerivative · entry 2 DENNER ALEXANDER J · CIK 0001361754 · 10% owner Sarissa Capital Management LP · CIK 0001577524 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 6,855,451 F2 · price: On March 5, 2025, the Reporting Persons sold 270,374 shares of Common Stock at a weighted average price of $17.6279 per share. The shares were sold in multiple open market transactions at prices ranging from $17.49 to $17.72 per share, inclusive. The Reporting Persons undertake to provide, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. F4 · ownership.nature: Sarissa Capital Management LP ("Sarissa Capital") is the investment advisor to Sarissa Capital Offshore Master Fund LP, Sarissa Capital Catapult Fund LLC, Sarissa Capital Hawkeye Fund LP and Sarissa Capital Master Fund II LP (collectively, the "Sarissa Funds") and may be deemed to beneficially own the shares of Common Stock directly beneficially owned by the Sarissa Funds by virtue of the authority granted to it to vote and to dispose of the securities held by them, including the shares of Common Stock. Alexander J. Denner, Ph.D., a citizen of the United States of America ("Dr. Denner"), is the Chief Investment Officer and ultimate general partner of Sarissa Capital and is the ultimate general partner, or controls the managing member, of each of the Sarissa Funds; accordingly, Dr. Denner may be deemed to beneficially own the shares of Common Stock directly held by the Sarissa Funds by virtue of such positions. F5 · ownership.nature: Each of Dr. Denner, Sarissa Capital and each of the Sarissa Funds disclaims beneficial ownership of the shares of Common Stock reported herein except, in each case, to the extent of their pecuniary interest therein. Read SEC document
March 04, 2025 Filed Mar 7, 2025 02:30 UTC	Innoviva, Inc. INVA · Entity 4679	SaleCommon Stock, par value $0.01 per share	151,175	$17.63	$2,665,079.19	Disclosure SEC source: 0000899140-25-000405 · form4.xml · nonDerivative · entry 1 DENNER ALEXANDER J · CIK 0001361754 · 10% owner Sarissa Capital Management LP · CIK 0001577524 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 7,125,825 F1 · price: On March 4, 2025, the Reporting Persons sold 151,175 shares of Common Stock at a weighted average price of $17.6291 per share. The shares were sold in multiple open market transactions at prices ranging from $17.55 to $17.89 per share, inclusive. The Reporting Persons undertake to provide, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. F4 · ownership.nature: Sarissa Capital Management LP ("Sarissa Capital") is the investment advisor to Sarissa Capital Offshore Master Fund LP, Sarissa Capital Catapult Fund LLC, Sarissa Capital Hawkeye Fund LP and Sarissa Capital Master Fund II LP (collectively, the "Sarissa Funds") and may be deemed to beneficially own the shares of Common Stock directly beneficially owned by the Sarissa Funds by virtue of the authority granted to it to vote and to dispose of the securities held by them, including the shares of Common Stock. Alexander J. Denner, Ph.D., a citizen of the United States of America ("Dr. Denner"), is the Chief Investment Officer and ultimate general partner of Sarissa Capital and is the ultimate general partner, or controls the managing member, of each of the Sarissa Funds; accordingly, Dr. Denner may be deemed to beneficially own the shares of Common Stock directly held by the Sarissa Funds by virtue of such positions. F5 · ownership.nature: Each of Dr. Denner, Sarissa Capital and each of the Sarissa Funds disclaims beneficial ownership of the shares of Common Stock reported herein except, in each case, to the extent of their pecuniary interest therein. Read SEC document
December 16, 2024 Filed Dec 18, 2024 21:05 UTC	IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213	GrantClass A Common Stock	4,249	$0.00	$0.00	Disclosure SEC source: 0000950170-24-137870 · ownership.xml · nonDerivative · entry 1 DENNER ALEXANDER J · CIK 0001361754 · Director · 10% owner Sarissa Capital Management LP · CIK 0001577524 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 156,353 F1 · kind: Issued pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024. Read SEC document
September 16, 2024 Filed Sep 18, 2024 20:05 UTC	IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213	GrantClass A Common Stock	3,282	$0.00	$0.00	Disclosure SEC source: 0000950170-24-107770 · ownership.xml · nonDerivative · entry 1 DENNER ALEXANDER J · CIK 0001361754 · Director · 10% owner Sarissa Capital Management LP · CIK 0001577524 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 152,104 F1 · kind: Issued pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024. Read SEC document
June 18, 2024 Filed Jun 21, 2024 20:05 UTC	IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213	GrantClass A Common Stock	24,311	$0.00	$0.00	Disclosure SEC source: 0000950170-24-076216 · ownership.xml · nonDerivative · entry 1 DENNER ALEXANDER J · CIK 0001361754 · Director · 10% owner Sarissa Capital Management LP · CIK 0001577524 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 148,822 F1 · kind: The restricted stock, granted pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year. Read SEC document
June 15, 2024 Filed Jun 18, 2024 20:05 UTC	IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213	GrantClass A Common Stock	2,572	$0.00	$0.00	Disclosure SEC source: 0000950170-24-074833 · ownership.xml · nonDerivative · entry 1 DENNER ALEXANDER J · CIK 0001361754 · Director · 10% owner Sarissa Capital Management LP · CIK 0001577524 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 124,511 F1 · kind: Issued pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024. Read SEC document
March 15, 2024 Filed Mar 19, 2024 20:05 UTC	IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213	GrantClass A Common Stock	1,662	$0.00	$0.00	Disclosure SEC source: 0000950170-24-033454 · ownership.xml · nonDerivative · entry 1 DENNER ALEXANDER J · CIK 0001361754 · Director · 10% owner Sarissa Capital Management LP · CIK 0001577524 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 121,939 F1 · kind: Issued pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024. Read SEC document
December 15, 2023 Filed Dec 19, 2023 21:05 UTC	IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213	GrantClass A Common Stock	1,347	$0.00	$0.00	Disclosure SEC source: 0001209191-23-059112 · doc4.xml · nonDerivative · entry 1 DENNER ALEXANDER J · CIK 0001361754 · Director · 10% owner Sarissa Capital Management LP · CIK 0001577524 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,277 F1 · kind: Issued pursuant to the Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2023. Read SEC document
September 15, 2023 Filed Sep 19, 2023 21:04 UTC	IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213	GrantClass A Common Stock	1,798	$0.00	$0.00	Disclosure SEC source: 0001209191-23-049996 · doc4.xml · nonDerivative · entry 1 DENNER ALEXANDER J · CIK 0001361754 · Director · 10% owner Sarissa Capital Management LP · CIK 0001577524 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,930 F1 · kind: Issued pursuant to the Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2023. Read SEC document
June 20, 2023 Filed Jun 22, 2023 21:26 UTC	IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213	GrantClass A Common Stock	22,350	$0.00	$0.00	Disclosure SEC source: 0001209191-23-039133 · doc4.xml · nonDerivative · entry 1 DENNER ALEXANDER J · CIK 0001361754 · Director · 10% owner Sarissa Capital Management LP · CIK 0001577524 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,132 F1 · kind: The restricted stock, granted pursuant to the Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2023, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year. Read SEC document
June 15, 2023 Filed Jun 21, 2023 01:00 UTC	Innoviva, Inc. INVA · Entity 4679	PurchaseCommon Stock, par value $0.01 per share	62,000	$13.13	$814,196.40	Disclosure SEC source: 0000899140-23-000758 · form4.xml · nonDerivative · entry 1 DENNER ALEXANDER J · CIK 0001361754 · 10% owner Sarissa Capital Management LP · CIK 0001577524 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 7,277,000 F1 · price: On June 15, 2023, the Reporting Persons acquired 62,000 shares of Common Stock at a weighted average price of $13.1322 per share. The shares were purchased in multiple open market transactions at prices ranging from $13.075 to $13.18 per share, inclusive. The Reporting Persons undertake to provide, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. F2 · ownership.nature: Sarissa Capital Management LP ("Sarissa Capital") is the investment advisor to Sarissa Capital Offshore Master Fund LP, Sarissa Capital Catapult Fund LLC, Sarissa Capital Hawkeye Fund LP and Sarissa Capital Master Fund II LP (collectively, the "Sarissa Funds") and may be deemed to beneficially own the shares of Common Stock directly beneficially owned by the Sarissa Funds by virtue of the authority granted to it to vote and to dispose of the securities held by them, including the shares of Common Stock. Alexander J. Denner, Ph.D., a citizen of the United States of America ("Dr. Denner"), is the Chief Investment Officer and ultimate general partner of Sarissa Capital and is the ultimate general partner, or controls the managing member, of each of the Sarissa Funds; accordingly, Dr. Denner may be deemed to beneficially own the shares of Common Stock directly held by the Sarissa Funds by virtue of such positions. F3 · ownership.nature: Each of Dr. Denner, Sarissa Capital and each of the Sarissa Funds disclaims beneficial ownership of the shares of Common Stock reported herein except, in each case, to the extent of their pecuniary interest therein. Read SEC document
June 15, 2023 Filed Jun 20, 2023 20:05 UTC	IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213	GrantClass A Common Stock	1,359	$0.00	$0.00	Disclosure SEC source: 0001209191-23-038339 · doc4.xml · nonDerivative · entry 1 DENNER ALEXANDER J · CIK 0001361754 · Director · 10% owner Sarissa Capital Management LP · CIK 0001577524 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,782 F1 · kind: Issued pursuant to the Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2023. Read SEC document
June 06, 2023 Filed Jun 8, 2023 00:10 UTC	Innoviva, Inc. INVA · Entity 4679	PurchaseCommon Stock, par value $0.01 per share	8,000	$13.05	$104,384.00	Disclosure SEC source: 0000899140-23-000730 · form4.xml · nonDerivative · entry 2 DENNER ALEXANDER J · CIK 0001361754 · 10% owner Sarissa Capital Management LP · CIK 0001577524 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 7,215,000 F2 · price: On June 6, 2023, the Reporting Persons acquired 8,000 shares of Common Stock at a weighted average price of $13.048 per share. The shares were purchased in multiple open market transactions at prices ranging from $13.04 to $13.09 per share, inclusive. The Reporting Persons undertake to provide, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. F3 · ownership.nature: Sarissa Capital Management LP ("Sarissa Capital") is the investment advisor to Sarissa Capital Offshore Master Fund LP, Sarissa Capital Catapult Fund LLC, Sarissa Capital Hawkeye Fund LP and Sarissa Capital Master Fund II LP (collectively, the "Sarissa Funds") and may be deemed to beneficially own the shares of Common Stock directly beneficially owned by the Sarissa Funds by virtue of the authority granted to it to vote and to dispose of the securities held by them, including the shares of Common Stock. Alexander J. Denner, Ph.D., a citizen of the United States of America ("Dr. Denner"), is the Chief Investment Officer and ultimate general partner of Sarissa Capital and is the ultimate general partner, or controls the managing member, of each of the Sarissa Funds; accordingly, Dr. Denner may be deemed to beneficially own the shares of Common Stock directly held by the Sarissa Funds by virtue of such positions. F4 · ownership.nature: Each of Dr. Denner, Sarissa Capital and each of the Sarissa Funds disclaims beneficial ownership of the shares of Common Stock reported herein except, in each case, to the extent of their pecuniary interest therein. Read SEC document
June 05, 2023 Filed Jun 8, 2023 00:10 UTC	Innoviva, Inc. INVA · Entity 4679	PurchaseCommon Stock, par value $0.01 per share	7,000	$13.04	$91,296.80	Disclosure SEC source: 0000899140-23-000730 · form4.xml · nonDerivative · entry 1 DENNER ALEXANDER J · CIK 0001361754 · 10% owner Sarissa Capital Management LP · CIK 0001577524 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 7,207,000 F1 · price: On June 5, 2023, the Reporting Persons acquired 7,000 shares of Common Stock at a weighted average price of $13.0424 per share. The shares were purchased in multiple open market transactions at prices ranging from $13.005 to $13.20 per share, inclusive. The Reporting Persons undertake to provide, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. F3 · ownership.nature: Sarissa Capital Management LP ("Sarissa Capital") is the investment advisor to Sarissa Capital Offshore Master Fund LP, Sarissa Capital Catapult Fund LLC, Sarissa Capital Hawkeye Fund LP and Sarissa Capital Master Fund II LP (collectively, the "Sarissa Funds") and may be deemed to beneficially own the shares of Common Stock directly beneficially owned by the Sarissa Funds by virtue of the authority granted to it to vote and to dispose of the securities held by them, including the shares of Common Stock. Alexander J. Denner, Ph.D., a citizen of the United States of America ("Dr. Denner"), is the Chief Investment Officer and ultimate general partner of Sarissa Capital and is the ultimate general partner, or controls the managing member, of each of the Sarissa Funds; accordingly, Dr. Denner may be deemed to beneficially own the shares of Common Stock directly held by the Sarissa Funds by virtue of such positions. F4 · ownership.nature: Each of Dr. Denner, Sarissa Capital and each of the Sarissa Funds disclaims beneficial ownership of the shares of Common Stock reported herein except, in each case, to the extent of their pecuniary interest therein. Read SEC document
May 30, 2023 Filed May 30, 2023 23:01 UTC	Innoviva, Inc. INVA · Entity 4679	PurchaseCommon Stock, par value $0.01 per share	120,000	$13.01	$1,560,648.00	Disclosure SEC source: 0000899140-23-000696 · form4.xml · nonDerivative · entry 3 DENNER ALEXANDER J · CIK 0001361754 · 10% owner Sarissa Capital Management LP · CIK 0001577524 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 7,200,000 F3 · price: On May 30, 2023, the Reporting Persons acquired 120,000 shares of Common Stock at a weighted average price of $13.0054 per share. The shares were purchased in multiple open market transactions at prices ranging from $12.93 to $13.125 per share, inclusive. The Reporting Persons undertake to provide, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. F4 · ownership.nature: Sarissa Capital Management LP ("Sarissa Capital") is the investment advisor to Sarissa Capital Offshore Master Fund LP, Sarissa Capital Catapult Fund LLC, Sarissa Capital Hawkeye Fund LP and Sarissa Capital Master Fund II LP (collectively, the "Sarissa Funds") and may be deemed to beneficially own the shares of Common Stock directly beneficially owned by the Sarissa Funds by virtue of the authority granted to it to vote and to dispose of the securities held by them, including the shares of Common Stock. Alexander J. Denner, Ph.D., a citizen of the United States of America ("Dr. Denner"), is the Chief Investment Officer and ultimate general partner of Sarissa Capital and is the ultimate general partner, or controls the managing member, of each of the Sarissa Funds; accordingly, Dr. Denner may be deemed to beneficially own the shares of Common Stock directly held by the Sarissa Funds by virtue of such positions. F5 · ownership.nature: Each of Dr. Denner, Sarissa Capital and each of the Sarissa Funds disclaims beneficial ownership of the shares of Common Stock reported herein except, in each case, to the extent of their pecuniary interest therein. Read SEC document
May 26, 2023 Filed May 30, 2023 23:01 UTC	Innoviva, Inc. INVA · Entity 4679	PurchaseCommon Stock, par value $0.01 per share	30,000	$13.12	$393,729.00	Disclosure SEC source: 0000899140-23-000696 · form4.xml · nonDerivative · entry 2 DENNER ALEXANDER J · CIK 0001361754 · 10% owner Sarissa Capital Management LP · CIK 0001577524 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 7,080,000 F2 · price: On May 26, 2023, the Reporting Persons acquired 30,000 shares of Common Stock at a weighted average price of $13.1243 per share. The shares were purchased in multiple open market transactions at prices ranging from $13.011 to $13.14 per share, inclusive. The Reporting Persons undertake to provide, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. F4 · ownership.nature: Sarissa Capital Management LP ("Sarissa Capital") is the investment advisor to Sarissa Capital Offshore Master Fund LP, Sarissa Capital Catapult Fund LLC, Sarissa Capital Hawkeye Fund LP and Sarissa Capital Master Fund II LP (collectively, the "Sarissa Funds") and may be deemed to beneficially own the shares of Common Stock directly beneficially owned by the Sarissa Funds by virtue of the authority granted to it to vote and to dispose of the securities held by them, including the shares of Common Stock. Alexander J. Denner, Ph.D., a citizen of the United States of America ("Dr. Denner"), is the Chief Investment Officer and ultimate general partner of Sarissa Capital and is the ultimate general partner, or controls the managing member, of each of the Sarissa Funds; accordingly, Dr. Denner may be deemed to beneficially own the shares of Common Stock directly held by the Sarissa Funds by virtue of such positions. F5 · ownership.nature: Each of Dr. Denner, Sarissa Capital and each of the Sarissa Funds disclaims beneficial ownership of the shares of Common Stock reported herein except, in each case, to the extent of their pecuniary interest therein. Read SEC document
May 25, 2023 Filed May 30, 2023 23:01 UTC	Innoviva, Inc. INVA · Entity 4679	PurchaseCommon Stock, par value $0.01 per share	50,000	$13.09	$654,330.00	Disclosure SEC source: 0000899140-23-000696 · form4.xml · nonDerivative · entry 1 DENNER ALEXANDER J · CIK 0001361754 · 10% owner Sarissa Capital Management LP · CIK 0001577524 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 7,050,000 F1 · price: On May 25, 2023, the Reporting Persons acquired 50,000 shares of Common Stock at a weighted average price of $13.0866 per share. The shares were purchased in multiple open market transactions at prices ranging from $13.015 to $13.14 per share, inclusive. The Reporting Persons undertake to provide, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. F4 · ownership.nature: Sarissa Capital Management LP ("Sarissa Capital") is the investment advisor to Sarissa Capital Offshore Master Fund LP, Sarissa Capital Catapult Fund LLC, Sarissa Capital Hawkeye Fund LP and Sarissa Capital Master Fund II LP (collectively, the "Sarissa Funds") and may be deemed to beneficially own the shares of Common Stock directly beneficially owned by the Sarissa Funds by virtue of the authority granted to it to vote and to dispose of the securities held by them, including the shares of Common Stock. Alexander J. Denner, Ph.D., a citizen of the United States of America ("Dr. Denner"), is the Chief Investment Officer and ultimate general partner of Sarissa Capital and is the ultimate general partner, or controls the managing member, of each of the Sarissa Funds; accordingly, Dr. Denner may be deemed to beneficially own the shares of Common Stock directly held by the Sarissa Funds by virtue of such positions. F5 · ownership.nature: Each of Dr. Denner, Sarissa Capital and each of the Sarissa Funds disclaims beneficial ownership of the shares of Common Stock reported herein except, in each case, to the extent of their pecuniary interest therein. Read SEC document
May 19, 2023 Filed May 20, 2023 01:12 UTC Amendment	Innoviva, Inc. INVA · Entity 4679	PurchaseCommon Stock, par value $0.01 per share	36,000	$13.48	$485,146.80	Disclosure SEC source: 0000899140-23-000672 · form4.xml · nonDerivative · entry 3 DENNER ALEXANDER J · CIK 0001361754 · 10% owner Sarissa Capital Management LP · CIK 0001577524 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 7,000,000 F3 · price: On May 19, 2023, the Reporting Persons acquired 36,000 shares of Common Stock at a weighted average price of $13.4763 per share. The shares were purchased in multiple open market transactions at prices ranging from $13.47 to $13.49 per share, inclusive. The Reporting Persons undertake to provide, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. F4 · ownership.nature: Sarissa Capital Management LP ("Sarissa Capital") is the investment advisor to Sarissa Capital Offshore Master Fund LP, Sarissa Capital Catapult Fund LLC, Sarissa Capital Hawkeye Fund LP and Sarissa Capital Master Fund II LP (collectively, the "Sarissa Funds") and may be deemed to beneficially own the shares of Common Stock directly beneficially owned by the Sarissa Funds by virtue of the authority granted to it to vote and to dispose of the securities held by them, including the shares of Common Stock. Alexander J. Denner, Ph.D., a citizen of the United States of America ("Dr. Denner"), is the Chief Investment Officer and ultimate general partner of Sarissa Capital and is the ultimate general partner, or controls the managing member, of each of the Sarissa Funds; accordingly, Dr. Denner may be deemed to beneficially own the shares of Common Stock directly held by the Sarissa Funds by virtue of such positions. F5 · ownership.nature: Each of Dr. Denner, Sarissa Capital and each of the Sarissa Funds disclaims beneficial ownership of the shares of Common Stock reported herein except, in each case, to the extent of their pecuniary interest therein Read SEC document
May 18, 2023 Filed May 20, 2023 01:12 UTC Amendment	Innoviva, Inc. INVA · Entity 4679	PurchaseCommon Stock, par value $0.01 per share	10,000	$13.05	$130,538.00	Disclosure SEC source: 0000899140-23-000672 · form4.xml · nonDerivative · entry 2 DENNER ALEXANDER J · CIK 0001361754 · 10% owner Sarissa Capital Management LP · CIK 0001577524 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 6,964,000 F2 · price: On May 18, 2023, the Reporting Persons acquired 10,000 shares of Common Stock at a weighted average price of $13.0538 per share. The shares were purchased in multiple open market transactions at prices ranging from $13.01 to $13.07 per share, inclusive. The Reporting Persons undertake to provide, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. F4 · ownership.nature: Sarissa Capital Management LP ("Sarissa Capital") is the investment advisor to Sarissa Capital Offshore Master Fund LP, Sarissa Capital Catapult Fund LLC, Sarissa Capital Hawkeye Fund LP and Sarissa Capital Master Fund II LP (collectively, the "Sarissa Funds") and may be deemed to beneficially own the shares of Common Stock directly beneficially owned by the Sarissa Funds by virtue of the authority granted to it to vote and to dispose of the securities held by them, including the shares of Common Stock. Alexander J. Denner, Ph.D., a citizen of the United States of America ("Dr. Denner"), is the Chief Investment Officer and ultimate general partner of Sarissa Capital and is the ultimate general partner, or controls the managing member, of each of the Sarissa Funds; accordingly, Dr. Denner may be deemed to beneficially own the shares of Common Stock directly held by the Sarissa Funds by virtue of such positions. F5 · ownership.nature: Each of Dr. Denner, Sarissa Capital and each of the Sarissa Funds disclaims beneficial ownership of the shares of Common Stock reported herein except, in each case, to the extent of their pecuniary interest therein Read SEC document
May 18, 2023 Filed May 20, 2023 00:00 UTC	Innoviva, Inc. INVA · Entity 4679	PurchaseCommon Stock, par value $0.01 per share	10,000	$13.05	$130,538.00	Disclosure SEC source: 0000899140-23-000667 · form4.xml · nonDerivative · entry 2 DENNER ALEXANDER J · CIK 0001361754 · 10% owner Sarissa Capital Management LP · CIK 0001577524 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 6,964,000 F2 · price: On May 18, 2023, the Reporting Persons acquired 10,000 shares of Common Stock at a weighted average price of $13.0538 per share. The shares were purchased in multiple open market transactions at prices ranging from $13.01 to $13.07 per share, inclusive. The Reporting Persons undertake to provide, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. F3 · ownership.nature: Sarissa Capital Management LP ("Sarissa Capital") is the investment advisor to Sarissa Capital Offshore Master Fund LP, Sarissa Capital Catapult Fund LLC, Sarissa Capital Hawkeye Fund LP and Sarissa Capital Master Fund II LP (collectively, the "Sarissa Funds") and may be deemed to beneficially own the shares of Common Stock directly beneficially owned by the Sarissa Funds by virtue of the authority granted to it to vote and to dispose of the securities held by them, including the shares of Common Stock. Alexander J. Denner, Ph.D., a citizen of the United States of America ("Dr. Denner"), is the Chief Investment Officer and ultimate general partner of Sarissa Capital and is the ultimate general partner, or controls the managing member, of each of the Sarissa Funds; accordingly, Dr. Denner may be deemed to beneficially own the shares of Common Stock directly held by the Sarissa Funds by virtue of such positions. F4 · ownership.nature: Each of Dr. Denner, Sarissa Capital and each of the Sarissa Funds disclaims beneficial ownership of the shares of Common Stock reported herein except, in each case, to the extent of their pecuniary interest therein Read SEC document
May 17, 2023 Filed May 20, 2023 01:12 UTC Amendment	Innoviva, Inc. INVA · Entity 4679	PurchaseCommon Stock, par value $0.01 per share	50,000	$13.07	$653,690.00	Disclosure SEC source: 0000899140-23-000672 · form4.xml · nonDerivative · entry 1 DENNER ALEXANDER J · CIK 0001361754 · 10% owner Sarissa Capital Management LP · CIK 0001577524 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 6,954,000 F1 · price: On May 17, 2023, the Reporting Persons acquired 50,000 shares of Common Stock at a weighted average price of $13.0738 per share. The shares were purchased in multiple open market transactions at prices ranging from $13.00 to $13.13 per share, inclusive. The Reporting Persons undertake to provide, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. F4 · ownership.nature: Sarissa Capital Management LP ("Sarissa Capital") is the investment advisor to Sarissa Capital Offshore Master Fund LP, Sarissa Capital Catapult Fund LLC, Sarissa Capital Hawkeye Fund LP and Sarissa Capital Master Fund II LP (collectively, the "Sarissa Funds") and may be deemed to beneficially own the shares of Common Stock directly beneficially owned by the Sarissa Funds by virtue of the authority granted to it to vote and to dispose of the securities held by them, including the shares of Common Stock. Alexander J. Denner, Ph.D., a citizen of the United States of America ("Dr. Denner"), is the Chief Investment Officer and ultimate general partner of Sarissa Capital and is the ultimate general partner, or controls the managing member, of each of the Sarissa Funds; accordingly, Dr. Denner may be deemed to beneficially own the shares of Common Stock directly held by the Sarissa Funds by virtue of such positions. F5 · ownership.nature: Each of Dr. Denner, Sarissa Capital and each of the Sarissa Funds disclaims beneficial ownership of the shares of Common Stock reported herein except, in each case, to the extent of their pecuniary interest therein Read SEC document
May 17, 2023 Filed May 20, 2023 00:00 UTC	Innoviva, Inc. INVA · Entity 4679	PurchaseCommon Stock, par value $0.01 per share	50,000	$13.07	$653,690.00	Disclosure SEC source: 0000899140-23-000667 · form4.xml · nonDerivative · entry 1 DENNER ALEXANDER J · CIK 0001361754 · 10% owner Sarissa Capital Management LP · CIK 0001577524 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 6,954,000 F1 · price: On May 17, 2023, the Reporting Persons acquired 50,000 shares of Common Stock at a weighted average price of $13.0738 per share. The shares were purchased in multiple open market transactions at prices ranging from $13.00 to $13.13 per share, inclusive. The Reporting Persons undertake to provide, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. F3 · ownership.nature: Sarissa Capital Management LP ("Sarissa Capital") is the investment advisor to Sarissa Capital Offshore Master Fund LP, Sarissa Capital Catapult Fund LLC, Sarissa Capital Hawkeye Fund LP and Sarissa Capital Master Fund II LP (collectively, the "Sarissa Funds") and may be deemed to beneficially own the shares of Common Stock directly beneficially owned by the Sarissa Funds by virtue of the authority granted to it to vote and to dispose of the securities held by them, including the shares of Common Stock. Alexander J. Denner, Ph.D., a citizen of the United States of America ("Dr. Denner"), is the Chief Investment Officer and ultimate general partner of Sarissa Capital and is the ultimate general partner, or controls the managing member, of each of the Sarissa Funds; accordingly, Dr. Denner may be deemed to beneficially own the shares of Common Stock directly held by the Sarissa Funds by virtue of such positions. F4 · ownership.nature: Each of Dr. Denner, Sarissa Capital and each of the Sarissa Funds disclaims beneficial ownership of the shares of Common Stock reported herein except, in each case, to the extent of their pecuniary interest therein Read SEC document
May 11, 2023 Filed May 16, 2023 01:09 UTC	Innoviva, Inc. INVA · Entity 4679	PurchaseCommon Stock, par value $0.01 per share	290,000	$12.34	$3,577,411.00	Disclosure SEC source: 0000899140-23-000656 · form4.xml · nonDerivative · entry 1 DENNER ALEXANDER J · CIK 0001361754 · 10% owner Sarissa Capital Management LP · CIK 0001577524 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 6,904,000 F1 · price: On May 11, 2023, the Reporting Persons acquired 290,000 shares of Common Stock at a weighted average price of $12.3359 per share. The shares were purchased in multiple open market transactions at prices ranging from $12.25 to $12.43. The Reporting Persons undertake to provide, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. F2 · ownership.nature: Sarissa Capital Management LP ("Sarissa Capital") is the investment advisor to Sarissa Capital Offshore Master Fund LP, Sarissa Capital Catapult Fund LLC, Sarissa Capital Hawkeye Fund LP and Sarissa Capital Master Fund II LP (collectively, the "Sarissa Funds") and may be deemed to beneficially own the shares of Common Stock directly beneficially owned by the Sarissa Funds by virtue of the authority granted to it to vote and to dispose of the securities held by them, including the shares of Common Stock. Alexander J. Denner, Ph.D., a citizen of the United States of America ("Dr. Denner"), is the Chief Investment Officer and ultimate general partner of Sarissa Capital and is the ultimate general partner, or controls the managing member, of each of the Sarissa Funds; accordingly, Dr. Denner may be deemed to beneficially own the shares of Common Stock directly held by the Sarissa Funds by virtue of such positions. F3 · ownership.nature: Each of Dr. Denner, Sarissa Capital and each of the Sarissa Funds disclaims beneficial ownership of the shares of Common Stock reported herein except, in each case, to the extent of their pecuniary interest therein. Read SEC document
March 15, 2023 Filed Mar 17, 2023 20:05 UTC	IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213	GrantClass A Common Stock	1,438	$0.00	$0.00	Disclosure SEC source: 0001209191-23-019596 · doc4.xml · nonDerivative · entry 1 DENNER ALEXANDER J · CIK 0001361754 · Director · 10% owner Sarissa Capital Management LP · CIK 0001577524 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,423 F1 · kind: Issued pursuant to the Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2023. Read SEC document
December 15, 2022 Filed Dec 19, 2022 21:14 UTC	IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213	GrantClass A Common Stock	1,244	$0.00	$0.00	Disclosure SEC source: 0001209191-22-061864 · doc4.xml · nonDerivative · entry 1 DENNER ALEXANDER J · CIK 0001361754 · Director · 10% owner Sarissa Capital Management LP · CIK 0001577524 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,985 F1 · kind: Issued pursuant to the Director Compensation Policy, effective May 2019. Read SEC document
September 15, 2022 Filed Sep 19, 2022 20:05 UTC	IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213	GrantClass A Common Stock	1,374	$0.00	$0.00	Disclosure SEC source: 0001209191-22-050483 · doc4.xml · nonDerivative · entry 1 DENNER ALEXANDER J · CIK 0001361754 · Director · 10% owner Sarissa Capital Management LP · CIK 0001577524 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,741 F1 · kind: Issued pursuant to the Director Compensation Policy, effective May 2019. Read SEC document
June 15, 2022 Filed Jun 17, 2022 20:29 UTC	BIOGEN INC. BIIB · Entity 1675	GrantCommon Stock	1,370	$0.00	$0.00	Disclosure SEC source: 0001127602-22-017773 · form4.xml · nonDerivative · entry 1 DENNER ALEXANDER J · CIK 0001361754 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,099 Read SEC document
June 15, 2022 Filed Jun 18, 2022 00:11 UTC	IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213	GrantClass A Common Stock	1,222	$0.00	$0.00	Disclosure SEC source: 0001209191-22-038192 · doc4.xml · nonDerivative · entry 1 DENNER ALEXANDER J · CIK 0001361754 · Director · 10% owner Sarissa Capital Management LP · CIK 0001577524 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,367 F1 · kind: Issued pursuant to the Director Compensation Policy, effective May 2019. Read SEC document
June 01, 2022 Filed Jun 3, 2022 20:05 UTC	IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213	GrantClass A Common Stock	21,571	$0.00	$0.00	Disclosure SEC source: 0001209191-22-033974 · doc4.xml · nonDerivative · entry 1 DENNER ALEXANDER J · CIK 0001361754 · Director · 10% owner Sarissa Capital Management LP · CIK 0001577524 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,145 F1 · kind: The restricted stock, granted pursuant to the Director Compensation Policy effective May 2019, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year. Read SEC document
March 15, 2022 Filed Mar 17, 2022 20:06 UTC	IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213	GrantClass A Common Stock	1,152	$0.00	$0.00	Disclosure SEC source: 0001209191-22-019537 · doc4.xml · nonDerivative · entry 1 DENNER ALEXANDER J · CIK 0001361754 · Director · 10% owner Sarissa Capital Management LP · CIK 0001577524 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,574 F1 · kind: Issued pursuant to the Director Compensation Policy, effective May 2019. Read SEC document
December 15, 2021 Filed Dec 17, 2021 21:07 UTC	IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213	GrantClass A Common Stock	1,211	$0.00	$0.00	Disclosure SEC source: 0001209191-21-070237 · doc4.xml · nonDerivative · entry 1 DENNER ALEXANDER J · CIK 0001361754 · Director · 10% owner Sarissa Capital Management LP · CIK 0001577524 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,422 F1 · kind: Issued pursuant to the Director Compensation Policy, effective May 2019. Read SEC document
September 15, 2021 Filed Sep 17, 2021 20:46 UTC	IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213	GrantClass A Common Stock	1,137	$0.00	$0.00	Disclosure SEC source: 0001209191-21-056654 · doc4.xml · nonDerivative · entry 1 DENNER ALEXANDER J · CIK 0001361754 · Director · 10% owner Sarissa Capital Management LP · CIK 0001577524 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,211 F1 · kind: Issued pursuant to the Director Compensation Policy, effective May 2019. Read SEC document
July 01, 2021 Filed Jul 2, 2021 21:35 UTC	BIOGEN INC. BIIB · Entity 1675	GrantCommon Stock	775	$0.00	$0.00	Disclosure SEC source: 0001127602-21-021352 · form4.xml · nonDerivative · entry 1 DENNER ALEXANDER J · CIK 0001361754 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,729 Read SEC document
June 15, 2021 Filed Jun 16, 2021 20:30 UTC	IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213	GrantClass A Common Stock	1,229	$0.00	$0.00	Disclosure SEC source: 0001209191-21-040919 · doc4.xml · nonDerivative · entry 1 DENNER ALEXANDER J · CIK 0001361754 · Director · 10% owner Sarissa Capital Management LP · CIK 0001577524 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,074 F1 · kind: Issued pursuant to the Director Compensation Policy, effective May 2019. Read SEC document
June 02, 2021 Filed Jun 4, 2021 20:05 UTC	IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213	GrantClass A Common Stock	22,766	$0.00	$0.00	Disclosure SEC source: 0001209191-21-038186 · doc4.xml · nonDerivative · entry 1 DENNER ALEXANDER J · CIK 0001361754 · Director · 10% owner Sarissa Capital Management LP · CIK 0001577524 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,845 F1 · kind: The restricted stock, granted pursuant to the Director Compensation Policy effective May 2019, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year. Read SEC document
March 15, 2021 Filed Mar 17, 2021 20:08 UTC	IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213	GrantClass A Common Stock	1,235	$0.00	$0.00	Disclosure SEC source: 0001209191-21-021307 · doc4.xml · nonDerivative · entry 1 DENNER ALEXANDER J · CIK 0001361754 · Director · 10% owner Sarissa Capital Management LP · CIK 0001577524 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,079 F1 · kind: Issued pursuant to the Director Compensation Policy, effective May 2019. Read SEC document
March 10, 2021 Filed Mar 11, 2021 00:06 UTC	IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213	PurchaseClass A Common Stock	75,000	$10.54	$790,500.00	Disclosure SEC source: 0001567619-21-006050 · doc1.xml · nonDerivative · entry 3 DENNER ALEXANDER J · CIK 0001361754 · Director · 10% owner Sarissa Capital Management LP · CIK 0001577524 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 16,390,000 F2 · ownership.nature: Consists of shares that are held by Sarissa Capital Management LP ("Sarissa Capital") or by the funds and other investment vehicles (the "Sarissa Funds") for which Sarissa Capital serves as investment advisor. Dr. Denner is the Chief Investment Officer of Sarissa Capital and the managing member, general partner or other control party of the Sarissa Funds. By virtue of the foregoing, Dr. Denner may be deemed to indirectly beneficially own the shares that these funds directly beneficially own. Each of Sarissa Capital, the Sarissa Funds and Dr. Denner disclaims beneficial ownership of these shares except, in each case, to the extent of their pecuniary interest therein. Read SEC document
March 08, 2021 Filed Mar 11, 2021 00:06 UTC	IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213	PurchaseClass A Common Stock	150,000	$10.30	$1,545,000.00	Disclosure SEC source: 0001567619-21-006050 · doc1.xml · nonDerivative · entry 2 DENNER ALEXANDER J · CIK 0001361754 · Director · 10% owner Sarissa Capital Management LP · CIK 0001577524 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 16,315,000 F2 · ownership.nature: Consists of shares that are held by Sarissa Capital Management LP ("Sarissa Capital") or by the funds and other investment vehicles (the "Sarissa Funds") for which Sarissa Capital serves as investment advisor. Dr. Denner is the Chief Investment Officer of Sarissa Capital and the managing member, general partner or other control party of the Sarissa Funds. By virtue of the foregoing, Dr. Denner may be deemed to indirectly beneficially own the shares that these funds directly beneficially own. Each of Sarissa Capital, the Sarissa Funds and Dr. Denner disclaims beneficial ownership of these shares except, in each case, to the extent of their pecuniary interest therein. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.